An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

Completed · Phase 4

Conditions studied: Neoplasms

In brief

This open-label, multicenter, non-randomized study provided continued access to vemurafenib for eligible participants with BRAF V600 mutation-positive malignancy, who were previously enrolled and treated in an antecedent vemurafenib protocol and did not meet the protocol's criteria for disease progression, or were treated beyond progression and were still deriving clinical benefit (as assessed by investigator), and may have therefore potentially benefited from continued treatment with vemurafenib. Participants received treatment with oral vemurafenib at 960 milligrams (mg) twice daily (BID), 720 mg BID, or 480 mg BID, depending on the last dose in the antecedent protocol. Treatment continued until progression of disease or as long as the participant was deriving clinical benefit, as judged by the investigator (case-by-case decision with approval of the Medical Monitor), death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the Sponsor to terminate the study, whichever occurred first.

Key facts

Study ID

NCT01739764

Run by

Hoffmann-La Roche

People needed

215

Starts

2013-02-19

Expected to finish

2020-02-17

Last updated by the study team

2021-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BRAF V600 mutation-positive malignancy
• Prior eligibility for and on study treatment from an antecedent vemurafenib protocol
• Ability to begin treatment in the extension (rollover) protocol within 15 days following the last day of the study in the antecedent protocol
• Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use 2 adequate methods of contraception as defined by protocol during the course of this study and for at least 6 months after completion of study treatment

You may not qualify if…

• Adverse event requiring discontinuation of vemurafenib in the antecedent protocol
• Progressive disease during the antecedent protocol. If approval to treat beyond progression was already given in the antecedent protocol, the participant may roll over into the current protocol without sponsor approval. Under special circumstances, enrollment into this protocol and dosing beyond progression may be considered and will require approval of the sponsor
• Participants meeting any of the following exclusion criterion of the antecedent study at the time the participant is considered for the extension (rollover) study:
• Current, recent (within 28 days prior to Day 1), or planned use of any antitumor therapy outside this study
• Any other serious concomitant medical condition that, in the opinion of the investigator, would compromise the safety of the participant or compromise the participant's ability to participate in the study
• History of malabsorption or other clinically significant metabolic dysfunction
• History of clinically significant cardiac or pulmonary dysfunction as specified in antecedent study

Where it is running

• UCLA Department of Medicine — Los Angeles, California, United States
• Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center — Torrance, California, United States
• University of Chicago Medical Center; Medicine, Section of Pulmonary — Chicago, Illinois, United States
• Siouxland Regional Cancer Center d/b/a June E. Nylen Cancer Center — Sioux City, Iowa, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• New York University Medical Center PRIME — New York, New York, United States
• Evelyn H. Lauder Center — New York, New York, United States
• University of Pennsylvania Health System — Philadelphia, Pennsylvania, United States
• Mary Crowley Medical Research Center; Oncology — Dallas, Texas, United States
• M D Anderson Physician Network — Webster, Texas, United States
• University of Washington Seattle Cancer Care Alliance — Seattle, Washington, United States
• N.N. Alexandrov National Cancer Centre of Belarus — Minsk District, Belarus
• Institut Jules Bordet — Brussels, Belgium
• University Clinical Center of the Republic of Srpska — Banja Luka, Bosnia and Herzegovina
• University Clinic Centre Sarajevo — Sarajevo, Bosnia and Herzegovina
• Hospital das Clinicas - UFRGS — Porto Alegre, Rio Grande do Sul, Brazil
• McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology — Montreal, Quebec, Canada
• Clinical Hospital Center Sestre Milosrdnice — Zagreb, Croatia
• Clinical Hospital Centre Zagreb — Zagreb, Croatia
• Bank of Cyprus Oncology Center — Nicosia, Cyprus
• Medical Research Institute — Alexandria, Egypt
• National Cancer Institute — Cairo, Egypt
• Mansoura University Hospital — Dakahlia, Egypt
• Gharbia Cancer Society — Tanta, Egypt
• Highlands Oncology Group — Rogers, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.